Press Releases

NEWS RELEASE 07.27.2021

Amgen To Acquire Privately Held Teneobio For $900 Million In Cash With Future Contingent Milestone Payments

NEWS RELEASE 07.14.2021

Amgen And The International Federation of Psoriasis Associations Launch UPLIFT Innovation Challenge

NEWS RELEASE 07.08.2021

Tezepelumab Granted Priority Review By U.S. FDA

NEWS RELEASE 06.23.2021

Amgen Announces Approval Of Aimovig® (Erenumab) In Japan For The Suppression Of Onset Of Migraine Attacks In Adults

NEWS RELEASE 06.15.2021

Acclaimed Makeup Artist Allan Avendaño Opens Up About Personal Skin Condition: Provides INSIDE LOOK At Life With Plaque Psoriasis

NEWS RELEASE 06.04.2021

Amgen To Present At The Goldman Sachs 42nd Annual Global Healthcare Conference

NEWS RELEASE 06.04.2021

Results From Phase 2 CodeBreaK 100 Show LUMAKRAS™ (sotorasib) Is The First And Only KRAS G12C Inhibitor With Overall Survival Data

NEWS RELEASE 06.04.2021

Phase 2 Fight Trial Continues To Show Improved Overall Survival With Bemarituzumab Plus Chemotherapy In Patients With FGFR2b+ Gastric And Gastroesophageal Cancers

NEWS RELEASE 06.01.2021

Amgen to Webcast Investor Meeting at ASCO 2021

NEWS RELEASE 06.01.2021

Amgen and Kyowa Kirin to Jointly Develop and Commercialize KHK4083, a Phase 3-Ready, Potential First-In-Class Treatment for Atopic Dermatitis

NEWS RELEASE 05.28.2021

Amgen To Present At The 2021 Jefferies Healthcare Conference

NEWS RELEASE 05.28.2021

FDA Approves LUMAKRAS™ (Sotorasib), The First And Only Targeted Treatment For Patients With KRAS G12C-Mutated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer

NEWS RELEASE 05.19.2021

Amgen To Present AT the Cowen 2nd Annual Virtual Oncology Innovation Summit

NEWS RELEASE 05.19.2021

Amgen To Showcase New Data From Oncology Portfolio At ASCO 2021

NEWS RELEASE 05.13.2021

New Tezepelumab Data Continue To Strengthen Profile For A Broad Population Of Severe Asthma Patients

NEWS RELEASE 05.11.2021

Efficacy Of Repatha® (Evolocumab) Across High-Risk Patient Populations Reinforced At ACC.21

NEWS RELEASE 05.10.2021

Amgen Announces Tezepelumab Biologics License Application Submitted To U.S. FDA

NEWS RELEASE 05.06.2021

Amgen To Present At The 2021 Bank of America Merrill Lynch Healthcare Conference

NEWS RELEASE 05.05.2021

FDA Accepts Amgen's Supplemental New Drug Application For Otezla® (apremilast) For Adults With Mild-To-Moderate Plaque Psoriasis

NEWS RELEASE 04.28.2021

Amgen Provides Updated Information On LUMAKRAS™ (Sotorasib)¹ Dose Comparison Study

NEWS RELEASE 04.27.2021

Amgen Reports First Quarter 2021 Financial Results

NEWS RELEASE 04.23.2021

OTEZLA® (apremilast) Significantly Improved Measures Of Disease Severity In Adults With Mild-To-Moderate Plaque Psoriasis

NEWS RELEASE 04.22.2021

Amgen Announces Webcast Of 2021 First Quarter Financial Results

NEWS RELEASE 04.19.2021

Amgen's Investigational Targeted Treatment Bemarituzumab Granted Breakthrough Therapy Designation

NEWS RELEASE 04.19.2021

Amgen Launches Biomarker Assist™, a Program To Help More Patients With Non-Small Cell Lung Cancer Gain Access To Biomarker Testing

NEWS RELEASE 04.16.2021

Amgen Successfully Completes Acquisition Of Five Prime Therapeutics

NEWS RELEASE 03.30.2021

Amgen to Acquire Rodeo Therapeutics Corporation

NEWS RELEASE 03.11.2021

Amgen To Present At The Oppenheimer 31st Annual Healthcare Conference

NEWS RELEASE 03.04.2021

Amgen To Acquire Five Prime Therapeutics For $1.9 Billion in Cash

NEWS RELEASE 03.03.2021

Amgen Announces 2021 Second Quarter Dividend

NEWS RELEASE 03.02.2021

BLINCYTO® (Blinatumomab) Demonstrated Significantly Prolonged Event-Free Survival Compared With Consolidation Chemotherapy In Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia

NEWS RELEASE 02.26.2021

Tezepelumab Is The First Biologic To Significantly Reduce Exacerbations In Broad Population Of Patients With Severe, Uncontrolled Asthma

NEWS RELEASE 02.24.2021

Amgen To Present At The Cowen 41st Annual Healthcare Conference

NEWS RELEASE 02.22.2021

Amgen To Webcast Investor Meeting At AAAAI Virtual Annual Meeting

NEWS RELEASE 02.22.2021

Amgen Submits Supplemental New Drug Application for Otezla® (apremilast) for Adults with Mild-To-Moderate Plaque Psoriasis

NEWS RELEASE 02.16.2021

FDA Grants Sotorasib Priority Review Designation For The Treatment Of Patients With KRAS G12C-Mutated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer

NEWS RELEASE 02.09.2021

Amgen To Present At Guggenheim Healthcare Talks Oncology Day

NEWS RELEASE 02.03.2021

Amgen Sponsors Golden Ticket at BioLabs LA at The Lundquist Institute to Help Accelerate Life Science Startups

NEWS RELEASE 02.02.2021

Amgen Reports Fourth Quarter And Full Year 2020 Financial Results

NEWS RELEASE 01.29.2021

Amgen Announces Breakthrough Therapy Designation Granted For Sotorasib In China

NEWS RELEASE 01.28.2021

Amgen Announces Webcast Of 2020 Fourth Quarter And Full Year Financial Results

NEWS RELEASE 01.28.2021

Amgen's Investigational KRAS G12C Inhibitor Sotorasib Demonstrated Rapid, Deep And Durable Responses In Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

NEWS RELEASE 01.26.2021

Amgen To Webcast Investor Meeting At 2020 World Conference on Lung Cancer

NEWS RELEASE 01.12.2021

Amgen To Showcase Next Frontier Of Innovation In Lung Cancer Therapies At WCLC 2020

NEWS RELEASE 01.11.2021

Amgen To Achieve Carbon Neutrality By 2027

NEWS RELEASE 01.06.2021

Amgen To Present At The 39th Annual J.P. Morgan Healthcare Conference

Earnings